Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2023-11-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING NOTICE OF ADJOURNED EXTRAORDINARY GENERAL MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the adjournment of an Extraordinary General Meeting (EGM) of CSPC Pharmaceutical Group Limited. It references the original EGM notice, circular, and proxy form, and provides details about the new date and time for the adjourned meeting. It does not contain financial statements, audit information, or detailed management discussion. It is not a report but an announcement about the meeting schedule and procedural details. Therefore, it fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length is just over 5,000 characters but the content is clearly an announcement, not a full report or detailed presentation.
2023-11-03 English
VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a monoclonal antibody drug (SYS6011) for clinical trials by the National Medical Products Administration of China. The content is an announcement of a regulatory milestone related to the company's drug development, not a financial report, earnings release, or management discussion. The document is short (2200 characters) and serves as a public announcement of a significant event rather than a detailed report or filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents but rather a voluntary announcement of a clinical trial approval. Given the available categories, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-11-03 English
VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a product (Secukinumab Injection) by the National Medical Products Administration of China. It is a short announcement (2130 characters) and does not contain financial data, regulatory certifications, or detailed report content. It is not an annual report, earnings release, or any detailed financial or governance report. It is an announcement about a clinical trial approval, which is a regulatory or corporate update but does not fit into categories like M&A, capital update, or legal proceedings. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2023-11-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for CSPC Pharmaceutical Group Limited for the month ended 31 October 2023. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other agreements. The form code FF301 and the nature of the content indicate it is a regulatory filing related to share capital movements and compliance with exchange listing rules. It is not a full financial report, earnings release, or management discussion, but a compliance report on share capital movements. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is not merely an announcement but a formal regulatory submission.
2023-11-01 English
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a bivalent COVID-19 mRNA vaccine. It is an announcement of a regulatory milestone and does not contain financial statements, detailed financial data, or comprehensive report content. The document is relatively short (2743 characters) and serves as a public disclosure of a significant event rather than a full report or detailed filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The content is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-10-30 English
VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a drug (NBL-028) by the China National Medical Products Administration. It contains no financial data, no detailed report, and is relatively short (3105 characters). It is an announcement of a regulatory approval event rather than a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications. The document is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous announcements that do not fit other categories.
2023-10-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.